Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: Pharmaceuticals
- Symbol: NYSE:ZTS
- CUSIP: 98978V10
- Web: www.zoetis.com
- Market Cap: $30.73 billion
- Outstanding Shares: 490,796,000
- 50 Day Moving Avg: $57.03
- 200 Day Moving Avg: $53.95
- 52 Week Range: $45.28 - $63.11
Sales & Book Value:
- Trailing P/E Ratio: 36.38
- Foreward P/E Ratio: 23.45
- P/E Growth: 2.04
- Annual Revenue: $4.96 billion
- Price / Sales: 6.20
- Book Value: $3.28 per share
- Price / Book: 19.09
- Annual Dividend: $0.42
- Dividend Yield: 0.7%
- EBIDTA: $1.71 billion
- Net Margins: 14.10%
- Return on Equity: 72.96%
- Return on Assets: 12.51%
- Debt-to-Equity Ratio: 2.80%
- Current Ratio: 3.24%
- Quick Ratio: 1.73%
- Average Volume: 3.08 million shs.
- Beta: 1.07
- Short Ratio: 1.77
Frequently Asked Questions for Zoetis (NYSE:ZTS)
What is Zoetis' stock symbol?
Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."
How often does Zoetis pay dividends? What is the dividend yield for Zoetis?
Zoetis declared a quarterly dividend on Friday, May 12th. Stockholders of record on Thursday, June 15th will be given a dividend of $0.105 per share on Friday, September 1st. This represents a $0.42 dividend on an annualized basis and a dividend yield of 0.67%. The ex-dividend date is Tuesday, June 13th. View Zoetis' Dividend History.
How were Zoetis' earnings last quarter?
Zoetis Inc (NYSE:ZTS) posted its quarterly earnings data on Thursday, May, 4th. The company reported $0.53 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.05. The business had revenue of $1.23 billion for the quarter, compared to the consensus estimate of $1.20 billion. Zoetis had a net margin of 14.10% and a return on equity of 72.96%. The business's revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.48 EPS. View Zoetis' Earnings History.
When will Zoetis make its next earnings announcement?
What guidance has Zoetis issued on next quarter's earnings?
Zoetis updated its FY17 earnings guidance on Thursday, May, 4th. The company provided EPS guidance of $2.26-2.36 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.32. The company issued revenue guidance of $5.10-5.225 billion, compared to the consensus revenue estimate of $5.17 billion.
Where is Zoetis' stock going? Where will Zoetis' stock price be in 2017?
16 brokerages have issued 1 year price objectives for Zoetis' stock. Their forecasts range from $35.00 to $71.00. On average, they expect Zoetis' share price to reach $59.19 in the next twelve months. View Analyst Ratings for Zoetis.
What are analysts saying about Zoetis stock?
Here are some recent quotes from research analysts about Zoetis stock:
- 1. According to Zacks Investment Research, "Zoetis’ first-quarter results were better than expected, with the company surpassing bottom-line estimates along with revenues. The growth in revenues was driven by sales of companion animal products such as Simparica, Apoquel and Cytopoint while the livestock portfolio was driven by growth in swine, cattle and fish across the international markets. Zoetis’ expects to see stronger growth from its companion animal portfolio in 2017 driven by Apoquel and Cytopoint, further penetration of Simparica, and ongoing uptake of new vaccines. Favorable market conditions contributed to swine performance in China as well as cattle product sales in Brazil. The company maintained its outlook for 2017. The company received approval for Cytopoint in the European Union in Apr 2017 and in Canada in Mar 2017. Shares of Zoetis have outperformed the industry in the past one year." (5/10/2017)
- 2. Guggenheim analysts commented, "We are raising our PT for ZTS shares after a 4Q beat and a lower than expected FX headwind for '17. The increase in our PT is driven by multiple expansion. We arrive at our new PT by using a DCF analysis. ZTS's solid execution this quarter increases our confidence that it can exceed consensus expectations for '17+ and sustain its 21x forward P/E multiple. Upward earnings revisions could come from margin expansion, M&A, and launches. Therefore, the sell-off today, which we think is motivated by profit taking, is overdone, in our view. We believe the weakness (ZTS down 3% vs. S&P down 0.14%) presents a good buying opportunity for the stock." (2/16/2017)
Who are some of Zoetis' key competitors?
Some companies that are related to Zoetis include Mylan (MYL), Hospira (HSP), Catalent (CTLT), Mallinckrodt PLC (MNK), Akorn (AKRX), Neurocrine Biosciences (NBIX), The Medicines Company (MDCO), Ironwood Pharmaceuticals (IRWD), Pacira Pharmaceuticals (PCRX), Supernus Pharmaceuticals (SUPN), Horizon Pharma PLC (HZNP), Diplomat Pharmacy (DPLO), Eagle Pharmaceuticals (EGRX), Momenta Pharmaceuticals (MNTA), Lannett Company (LCI), Flexion Therapeutics (FLXN), Versartis (VSAR) and Karyopharm Therapeutics (KPTI).
Who owns Zoetis stock?
Zoetis' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.33%), Vanguard Group Inc. (6.66%), State Street Corp (4.33%), State Farm Mutual Automobile Insurance Co. (3.89%), Morgan Stanley (2.97%) and Independent Franchise Partners LLP (2.28%). Company insiders that own Zoetis stock include Andrew Fenton, Catherine A Knupp, Heidi C Chen, Kristin C Peck, Michael B Mccallister, Pershing Square Capital Manage and Roxanne Lagano. View Institutional Ownership Trends for Zoetis.
Who sold Zoetis stock? Who is selling Zoetis stock?
Zoetis' stock was sold by a variety of institutional investors in the last quarter, including Lazard Asset Management LLC, Principal Financial Group Inc., Marshall Wace LLP, Janus Capital Management LLC, Winslow Capital Management LLC, Alliancebernstein L.P., IronBridge Capital Management LP and Point72 Asset Management L.P.. Company insiders that have sold Zoetis stock in the last year include Andrew Fenton, Catherine A Knupp, Heidi C Chen, Kristin C Peck and Roxanne Lagano. View Insider Buying and Selling for Zoetis.
Who bought Zoetis stock? Who is buying Zoetis stock?
Zoetis' stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, Marshall Wace North America L.P., Waddell & Reed Financial Inc., California Public Employees Retirement System, State Street Corp, Prudential Financial Inc. and MARSHALL WACE ASIA Ltd. View Insider Buying and Selling for Zoetis.
How do I buy Zoetis stock?
Shares of Zoetis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Zoetis stock cost?
One share of Zoetis stock can currently be purchased for approximately $62.61.
Earnings History for Zoetis (NYSE:ZTS)Earnings History by Quarter for Zoetis (NYSE:ZTS)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/1/2017|| || || || || || || || |
|5/4/2017||Q1 2017||$0.48||$0.53||$1.20 billion||$1.23 billion||View||Listen|
|2/16/2017||Q416||$0.45||$0.47||$1.28 billion||$1.30 billion||View||N/A|
|11/2/2016||Q316||$0.46||$0.52||$1.22 billion||$1.20 billion||View||N/A|
|8/3/2016||Q216||$0.44||$0.49||$1.17 billion||$1.20 billion||View||N/A|
|5/4/2016||Q116||$0.41||$0.48||$1.10 billion||$1.20 billion||View||N/A|
|2/16/2016||Q415||$0.39||$0.43||$1.25 billion||$1.30 billion||View||Listen|
|11/3/2015||Q315||$0.40||$0.50||$1.18 billion||$1.20 billion||View||N/A|
|8/4/2015||Q215||$0.38||$0.43||$1.12 billion||$1.20 billion||View||N/A|
|5/5/2015||Q115||$0.37||$0.41||$1.11 billion||$1.10 billion||View||N/A|
|2/11/2015||Q414||$0.36||$0.40||$1.27 billion||$1.30 billion||View||N/A|
|11/4/2014||Q314||$0.37||$0.41||$1.16 billion||$1.20 billion||View||N/A|
|5/6/2014||Q114||$0.37||$0.38||$1.13 billion||$1.10 billion||View||N/A|
|2/11/2014||Q413||$0.34||$0.36||$1.21 billion||$1.25 billion||View||N/A|
|11/5/2013||Q313||$0.34||$0.34||$1.07 billion||$1.10 billion||View||N/A|
|8/6/2013||Q2 2013||$0.36||$0.36||$1.13 billion||$1.11 billion||View||N/A|
|4/30/2013||Q1 2013||$0.27||$0.36||$1.24 billion||$1.09 billion||View||N/A|
Earnings Estimates for Zoetis (NYSE:ZTS)
2017 EPS Consensus Estimate: $2.25
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Current Dividend Information for Zoetis (NYSE:ZTS)
|Dividend Growth:||24.90% (3 Year Average)|
|Payout Ratio:||30.44% (Trailing 12 Months of Earnings) |
17.95% (Based on This Year's Estimates)
15.73% (Based on Next Year's Estimates)
|Track Record:||3 Years of Consecutive Dividend Growth|
Dividend History by Quarter for Zoetis (NYSE:ZTS)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Zoetis (NYSE:ZTS)
Insider Ownership Percentage: 0.05%Insider Trades by Quarter for Zoetis (NYSE:ZTS)
Institutional Ownership Percentage: 94.54%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/12/2017||Catherine A Knupp||Insider||Sell||5,785||$60.16||$348,025.60|| |
|11/22/2016||Kristin C Peck||Insider||Sell||10,092||$49.55||$500,058.60|| |
|11/8/2016||Roxanne Lagano||Insider||Sell||9,797||$50.43||$494,062.71|| |
|9/6/2016||Michael B Mccallister||Director||Buy||2,000||$51.34||$102,680.00|| |
|9/2/2016||Andrew Fenton||Insider||Sell||13,870||$51.25||$710,837.50|| |
|9/1/2016||Heidi C Chen||Insider||Sell||32,097||$50.98||$1,636,305.06|| |
|5/9/2016||Pershing Square Capital Manage||Director||Sell||16,850,000||$46.55||$784,367,500.00|| |
|8/8/2013||Michael Mccallister||Director||Buy||7,000||$31.35||$219,450.00|| |
|2/6/2013||Frank A Damelio||Director||Buy||5,000||$26.00||$130,000.00|| |
|2/6/2013||Sandra J Beaty||EVP||Buy||2,000||$26.00||$52,000.00|| |
Headline Trends for Zoetis (NYSE:ZTS)
Latest Headlines for Zoetis (NYSE:ZTS)
Zoetis (ZTS) Chart for Friday, May, 26, 2017